These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24453831)

  • 41. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA.
    McCabe DJ; Harrison P; Mackie IJ; Sidhu PS; Lawrie AS; Purdy G; Machin SJ; Brown MM
    Platelets; 2005 Aug; 16(5):269-80. PubMed ID: 16011977
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
    Breet NJ; van Werkum JW; Bouman HJ; Kelder JC; Ruven HJ; Bal ET; Deneer VH; Harmsze AM; van der Heyden JA; Rensing BJ; Suttorp MJ; Hackeng CM; ten Berg JM
    JAMA; 2010 Feb; 303(8):754-62. PubMed ID: 20179285
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: platelet reactivity in an observational study.
    Nührenberg TG; Trenk D; Leggewie S; Ristau I; Amann M; Stratz C; Hochholzer W; Valina CM; Neumann FJ
    Platelets; 2013; 24(7):549-53. PubMed ID: 23216528
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expression of platelet surface receptors and early changes in platelet function in patients with STEMI treated with abciximab and clopidogrel versus clopidogrel alone.
    Konopka A; Spychalska J; Sitkiewicz D; Zdebska E; Pilichowska I; Piotrowski W; Stepińska J
    Am J Cardiovasc Drugs; 2007; 7(6):433-9. PubMed ID: 18076210
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Persistent platelet activation is related to very early cardiovascular events in patients with acute coronary syndromes.
    Małek ŁA; Spiewak M; Filipiak KJ; Grabowski M; Szpotańska M; Rosiak M; Główczyńska R; Imiela T; Huczek Z; Opolski G
    Kardiol Pol; 2007 Jan; 65(1):40-5; discussion 46. PubMed ID: 17295159
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy.
    Saw J; Densem C; Walsh S; Jokhi P; Starovoytov A; Fox R; Wong G; Buller C; Ricci D; Mancini GB; Fung A
    JACC Cardiovasc Interv; 2008 Dec; 1(6):654-9. PubMed ID: 19463380
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Changes in coagulation and fibrinolysis in the patients with coronary heart disease in acute period and effect of drug intervention].
    Jia XQ; Dong CM; Qin J; Zhang L
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2012 Apr; 24(4):225-8. PubMed ID: 22464576
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Yu J; Mehran R; Baber U; Ooi SY; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Brodie BR; Stuckey TD; Maehara A; Xu K; Ben-Yehuda O; Kirtane AJ; Stone GW
    Circ Cardiovasc Interv; 2017 Feb; 10(2):. PubMed ID: 28193677
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study.
    Sabatine MS; Cannon CP; Gibson CM; López-Sendón JL; Montalescot G; Theroux P; Lewis BS; Murphy SA; McCabe CH; Braunwald E;
    JAMA; 2005 Sep; 294(10):1224-32. PubMed ID: 16143698
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of the role of the new INNOVANCE PFA P2Y test cartridge in detection of clopidogrel resistance.
    Tsantes A; Ikonomidis I; Papadakis I; Kottaridi C; Tsante A; Kalamara E; Kardoulaki A; Kopterides P; Kapsimali V; Karakitsos P; Lekakis J; Travlou A
    Platelets; 2012; 23(6):481-9. PubMed ID: 22646492
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y.
    Linnemann B; Schwonberg J; Rechner AR; Mani H; Lindhoff-Last E
    Ann Hematol; 2010 Jun; 89(6):597-605. PubMed ID: 20049442
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness of Platelet Function Analyzer-100 for Laboratory Detection of Anti-Platelet Drug-Induced Platelet Dysfunction.
    Kweon OJ; Lim YK; Kim B; Lee MK; Kim HR
    Ann Lab Med; 2019 Jan; 39(1):23-30. PubMed ID: 30215226
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.
    Tsantes AE; Ikonomidis I; Papadakis I; Bonovas S; Gialeraki A; Kottaridi C; Kyriakou E; Kokori S; Douramani P; Kopterides P; Karakitsos P; Lekakis J; Kapsimali V
    Thromb Res; 2013 Aug; 132(2):e105-11. PubMed ID: 23830212
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predictors of high on-aspirin platelet reactivity in high-risk vascular patients treated with single or dual antiplatelet therapy.
    Amsallem M; Manzo-Silberman S; Dillinger JG; Sideris G; Voicu S; Bal dit Sollier C; Drouet L; Henry P
    Am J Cardiol; 2015 May; 115(9):1305-10. PubMed ID: 25759104
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes.
    Eikelboom JW; Weitz JI; Budaj A; Zhao F; Copland I; Maciejewski P; Johnston M; Yusuf S
    Eur Heart J; 2002 Nov; 23(22):1771-9. PubMed ID: 12419297
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions.
    Lepäntalo A; Virtanen KS; Heikkilä J; Wartiovaara U; Lassila R
    Eur Heart J; 2004 Mar; 25(6):476-83. PubMed ID: 15039127
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized controlled trial of aspirin and clopidogrel versus aspirin and placebo on markers of smooth muscle proliferation before and after peripheral angioplasty.
    Wilson AM; Brittenden J; Bachoo P; Ford I; Nixon GF
    J Vasc Surg; 2009 Oct; 50(4):861-9. PubMed ID: 19786240
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
    Christ G; Siller-Matula JM; Francesconi M; Dechant C; Grohs K; Podczeck-Schweighofer A
    BMJ Open; 2014 Oct; 4(10):e005781. PubMed ID: 25361837
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin.
    Siller-Matula JM; Delle-Karth G; Christ G; Neunteufl T; Maurer G; Huber K; Tolios A; Drucker C; Jilma B
    Int J Cardiol; 2013 Jul; 167(2):430-5. PubMed ID: 22305813
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sensitive and specific assessment of recombinant von Willebrand factor in platelet function analyzer.
    Pekrul I; Kragh T; Turecek PL; Novack AR; Ott HW; Spannagl M
    Platelets; 2019; 30(2):264-270. PubMed ID: 29319374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.